Hydrogen will be infused into aqueous solution (normal saline or water) at as high a concentration as possible (saturation = 1.6 ppm), and administered intravenously or orally respectively, q 8 hours for 3 days.
Similarly, Minocycline will be administered either i.v. or p.o. once daily for 5 days.

Normal saline will be substituted for both Hydrogen and Minocycline for intravenous administration. Water will be substituted for hydrogen when administered p.o., and placebo capsules will be substituted for minocycline.

Stroke, Ischemic

Hydrogen will be infused into bags of normal saline solution and administered intravenously, or infused into water for the patient to drink, as the patient's condition permits. This will be administered q 8 hours for 3 days.

Hydrogen

Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.
Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period.

Minocycline

Normal saline solution or water will be administered i.v. or p.o. respectively, in place of hydrogen solution.

Placebo Hydrogen

Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.

Placebo Minocycline

Stony Brook University Hospital

Neuroprotection in Acute Ischemic Stroke

Pilot Study of the Neuroprotective Effects of Hydrogen and Minocycline in Acute Ischemic Stroke

rating scale to assess level of functional independence for patients post-stroke. Scores range from 0 (no symptoms) to 6 (dead).

15-item neurologic examination scale for severity of stroke. Ratings for each item are scored with 3 to 5 grades. A total NIHSS of 0 is normal; 1-4 is considered a minor stroke; 5-15 moderate; 16-20 moderate to severe; and 21-42 severe.

Adrian Marchidann

Assistant Professor, Neurology Dept.

Stony Brook University

Korea Institute of Science and Technology

Patients with CKD stage 2 & 3 (eGFR 30-89ml/min/1.73m2) will be randomly assigned to receive either spironolactone or chlortalidone in a PROBE design.
Subjects will undergo cardiac MRI, carotid femoral pulse wave velocity, 24 hour ambulatory blood pressure monitoring, blood tests for renal function and spot urine analysis for proteinuria (albumin:creatinine ratio) at baseline and after 40 weeks of allocated treatment. Additional blood tests for renal function and potassium level will be assessed at week 1,2,4,8 and 20.

Renal Insufficiency, Chronic

Cardio-Renal Syndrome

Spironolactone

Chlortalidone

Departments of Cardiology & Nephrology University Hospital Birmingham

Cambridge Clinical Trials Unit, University of Cambridge and Addenbrooke's Hospital

University of Edinburgh: BHF Centre for Cardiovascular Science and Western General Hospital

Royal Free Hospital

Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD

A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)

Potassium will be assessed at baseline, week 1,2,4,8,20 and week 40

Patients will wear an ambulatory monitor at week 0 and 40

Global longitudinal strain (%) will be assessed at week 0 and 40

Estimated GFR will calculated using the Modification of Diet in Renal Disease equation at baseline, week 1,2,4,8,20 and week 40

Dr JN Townend

Professor of Cardiology

University Hospital Birmingham

Royal Free Hospital NHS Foundation Trust

University of Edinburgh

University of Cambridge

USPIO given 2-4 days post MI Ferumoxytol enhanced MRI

USPIO given 5-7 days post MI Ferumoxytol enhanced MRI

USPIO given 11-21 days post MI Ferumoxytol enhanced MRI

Myocardial Infarction

Inflammation

Ferumoxytol enhanced MRI

Royal Infirmary of Edinburgh

Clinical Research Imaging Centre

IRon Nanoparticle Enhanced MRI in the Assessment of Myocardial infarctioN

ASSESSMENT OF CELLULAR INFLAMMATION FOLLOWING ACUTE MYOCARDIAL INFARCTION Application Of Ultrasmall Superparamagnetic Particles Of Iron Oxide

Marker of USPIO uptake (and inflammation) in each cohort after myocardial infarction.
The USPIO infusion is given at different time-points for each cohort. However only the R2* value on the MRI 24 hours after infusion will constitute the primary end-point

proteinase/경색증

Neuroprotection in Acute Ischemic Stroke

Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD

IRon Nanoparticle Enhanced MRI in the Assessment of Myocardial infarctioN

과학이 뒷받침하는 가장 완벽한 약초 데이터베이스